20.80
-0.49 (-2.30%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Fortrea Holdings Inc. | Bearish | Bearish |
Stockmoo Score
|
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (Citigroup, 44.23%) | Buy |
| Median | 23.00 (10.58%) | |
| Low | 21.00 (B of A Securities, 0.96%) | Sell |
| 21.00 (Barclays, 0.96%) | Hold | |
| Average | 24.00 (15.39%) | |
| Total | 2 Buy, 4 Hold, 1 Sell | |
| Avg. Price @ Call | 22.25 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Deutsche Bank | 20 Aug 2024 | 23.00 (10.58%) | Hold | 22.41 |
| B of A Securities | 13 Aug 2024 | 21.00 (0.96%) | Sell | 22.22 |
| 18 Jul 2024 | 26.00 (25.00%) | Sell | 25.85 | |
| Baird | 13 Aug 2024 | 28.00 (34.62%) | Buy | 22.22 |
| Barclays | 13 Aug 2024 | 21.00 (0.96%) | Hold | 22.22 |
| 25 Jul 2024 | 30.00 (44.23%) | Hold | 26.22 | |
| Citigroup | 13 Aug 2024 | 30.00 (44.23%) | Buy | 22.22 |
| Evercore ISI Group | 13 Aug 2024 | 22.00 (5.77%) | Hold | 22.22 |
| 08 Aug 2024 | 27.00 (29.81%) | Hold | 24.62 | |
| TD Cowen | 13 Aug 2024 | 23.00 (10.58%) | Hold | 22.22 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Aug 2024 | Announcement | Fortrea Reports Second Quarter 2024 Results |
| 17 Jul 2024 | Announcement | Fortrea Announces Date for Second Quarter 2024 Financial Results and Conference Call |
| 11 Jul 2024 | Announcement | Fortrea Appoints Robert Parks as Chief Accounting Officer |
| 27 Jun 2024 | Announcement | Fortrea Launches AI Innovation Studio to Galvanize Technology and Human Solutions to Improve Clinical Trial Delivery |
| 19 Jun 2024 | Announcement | Fortrea to Participate in Virtual Fireside Chat with Evercore ISI |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |